Home » Stocks » AKCA

Akcea Therapeutics, Inc. (AKCA)

Oct 13, 2020 - AKCA was delisted after being acquired by IONS
Stock Price: $18.17 USD 0.00 (0.00%)
Updated Oct 12, 2020 4:00 PM EDT
Market Cap 1.85B
Revenue (ttm) 336.55M
Net Income (ttm) -41.52M
Shares Out 101.48M
EPS (ttm) -0.56
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day Oct 12, 2020
Last Price $18.17
Previous Close $18.17
Change ($) 0.00
Change (%) 0.00%
Day's Open -
Day's Range 18.13 - 18.17
Day's Volume 0
52-Week Range 8.00 - 21.71

News

Hide News
PRNewsWire - 3 months ago

NEW YORK, Sept. 26, 2020 /PRNewswire/ -- Halper Sadeh LLP, a global investor rights law firm, is investigating: Akcea Therapeutics, Inc. (NASDAQ: AKCA) concerning potential violations of the f...

PRNewsWire - 3 months ago

NEW YORK, Sept. 25, 2020 /PRNewswire/ -- Akcea Therapeutics, Inc. (NASDAQ: AKCA) Lifshitz Law Firm, P.C. announces investigation into possible breach of fiduciary duties in connection with the...

Business Wire - 4 months ago

LONDON--(BUSINESS WIRE)--Akcea Therapeutics UK Ltd., a subsidiary of Akcea Therapeutics Inc.

PRNewsWire - 4 months ago

PHILADELPHIA, Sept. 5, 2020 /PRNewswire/ -- Kaskela Law LLC announces that it is investigating Akcea Therapeutics, Inc.

Business Wire - 4 months ago

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq.

PRNewsWire - 4 months ago

NEW YORK, Sept. 1, 2020 /PRNewswire/ -- Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a national securities firm headquartered at the Empire State Building in Ne...

Zacks Investment Research - 4 months ago

Ionis (IONS) is set to acquire the remaining 24% stake in Akcea Therapeutics (AKCA) in an all-cash deal.

Other stocks mentioned: IONS
PRNewsWire - 4 months ago

SAN DIEGO, Sept. 1, 2020 /PRNewswire/ -- Shareholder rights law firm Johnson Fistel, LLP has launched an investigation into whether the board members of Akcea Therapeutics, Inc.

PRNewsWire - 4 months ago

NEW YORK, Aug. 31, 2020 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Akcea Therapeutics, Inc.

The Motley Fool - 4 months ago

The biotech is being acquired by its largest shareholder.

Other stocks mentioned: IONS
Newsfile Corp - 4 months ago

(Newsfile Corp. - August 31, 2020) - The following statement is being issued by Levi & Korsinsky, LLP:To view an enhanced version of this graphic, please visit:https://orders ewsfilecorp.com...

Other stocks mentioned: IONS
24/7 Wall Street - 4 months ago

Akcea Therapeutics Inc. (NASDAQ: AKCA) stock jumped on Monday after it was announced that Ionis Pharmaceuticals Inc.

Other stocks mentioned: IONS
Benzinga - 4 months ago

Akcea Therapeutics Inc (NASDAQ: AKCA) shares were rallying strongly Monday following a buyout deal.

Other stocks mentioned: IONS
PRNewsWire - 4 months ago

CARLSBAD, Calif. and BOSTON, Aug.

Seeking Alpha - 5 months ago

Akcea Therapeutics, Inc. (AKCA) CEO Damien McDevitt on Q2 2020 Results - Earnings Call Transcript

Zacks Investment Research - 5 months ago

Akcea Therapeutics (AKCA) delivered earnings and revenue surprises of -113.33% and -47.10%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the ...

PRNewsWire - 5 months ago

BOSTON, Aug. 4, 2020 /PRNewswire/ -- Akcea Therapeutics, Inc.

Zacks Investment Research - 5 months ago

Akcea Therapeutics (AKCA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Investment Research - 5 months ago

Investors will focus on regular top and bottom-line numbers along with its pipeline progress, when Akcea (AKCA) reports Q2 results.

PRNewsWire - 5 months ago

BOSTON, July 21, 2020 /PRNewswire/ -- Akcea Therapeutics, Inc. (NASDAQ:AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc.

PRNewsWire - 5 months ago

BOSTON, July 20, 2020 /PRNewswire/ -- Akcea Therapeutics, Inc. (NASDAQ: AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc.

PRNewsWire - 6 months ago

BOSTON, July 9, 2020 /PRNewswire/ -- Akcea Therapeutics, Inc. (NASDAQ: AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., today announced that William Andrews, MD, FACP, has joi...

Zacks Investment Research - 6 months ago

Akcea Therapeutics (AKCA) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near t...

PRNewsWire - 7 months ago

BOSTON, June 17, 2020 /PRNewswire/ -- Akcea Therapeutics, Inc. (NASDAQ:AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., focused on developing and commercializing drugs to trea...

Seeking Alpha - 7 months ago

Akcea: Uninteresting Slow Growth Stock With Long-Term Potential

PRNewsWire - 7 months ago

BOSTON, June 9, 2020 /PRNewswire/ -- Akcea Therapeutics, Inc. (NASDAQ: AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., today announced that Kia Motesharei, Ph.D., has joined ...

PRNewsWire - 7 months ago

BOSTON, June 8, 2020 /PRNewswire/ -- Akcea Therapeutics, Inc. (NASDAQ: AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., today announced that AIFA, or The Italian Medicines Age...

PRNewsWire - 7 months ago

BOSTON, June 1, 2020 /PRNewswire/ -- Akcea Therapeutics, Inc. (NASDAQ: AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., today announced the Portuguese Medicine Regulatory Auth...

GlobeNewsWire - 7 months ago

Results from the ongoing, open-label extension (OLE) study of the pivotal NEURO-TTR trial published in the European Journal of Neurology show that patients treated with TEGSEDI® (inotersen) ex...

PRNewsWire - 8 months ago

BOSTON, May 18, 2020 /PRNewswire/ -- Akcea Therapeutics, Inc. (NASDAQ: AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., today announced that Michael D. Price has joined the co...

PRNewsWire - 8 months ago

BOSTON, May 14, 2020 /PRNewswire/ -- Akcea Therapeutics, Inc. (NASDAQ: AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., today announced The Ministry of Health of Spain (MSCBS)...

Zacks Investment Research - 8 months ago

Akcea (AKCA) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

Seeking Alpha - 8 months ago

Akcea Therapeutics, Inc. (AKCA) CEO Damien McDevitt on Q1 2020 Results - Earnings Call Transcript

Zacks Investment Research - 8 months ago

Akcea Therapeutics (AKCA) delivered earnings and revenue surprises of 6.67% and -70.23%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the st...

Zacks Investment Research - 8 months ago

Akcea Therapeutics (AKCA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

GlobeNewsWire - 9 months ago

BOSTON, March 24, 2020 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ: AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., announced today that its board of directors has...

GlobeNewsWire - 10 months ago

BOSTON, March 11, 2020 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ: AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., today announced that Lisa Johnson-Pratt, M.D., ...

Seeking Alpha - 10 months ago

Akcea Therapeutics, Inc. (AKCA) CEO Damien McDevitt on Q4 2019 Results - Earnings Call Transcript

GlobeNewsWire - 11 months ago

BOSTON, Feb. 13, 2020 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ: AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., today announced the appointment of Amber Salzman...

The Motley Fool - 11 months ago

Both primary as well as multiple secondary endpoints were met in the trial.

Other stocks mentioned: IONS
GlobeNewsWire - 11 months ago

Favorable safety and tolerability were observed

The Motley Fool - 11 months ago

The drug will advance to studies in familial chylomicronemia syndrome and other diseases that result in high triglyceride levels.

Other stocks mentioned: IONS
Investors Business Daily - 11 months ago

Shares of Ionis Pharmaceuticals and Akcea Therapeutics popped Wednesday after the biotech companies said their high triglycerides treatment succeeded in a midstage study. The post Will These ...

Other stocks mentioned: IONS
24/7 Wall Street - 11 months ago

Akcea Therapeutics Inc. (NASDAQ: AKCA) and Ionis Pharmaceuticals Inc. (NASDAQ: IONS) each made handy gains on Wednesday after they reported midstage results for their cardiovascular disease st...

Other stocks mentioned: IONS
GlobeNewsWire - 1 year ago

BOSTON and CARLSBAD, Calif., Jan. 10, 2020 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ: AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., and Ionis Pharmaceuticals, ...

Other stocks mentioned: IONS
GlobeNewsWire - 1 year ago

Patients treated with AKCEA-APO(a)-LRx received pre-specified endpoints for Lp(a) levels with favorable safety and tolerability profile

GlobeNewsWire - 1 year ago

Data from Phase 2 clinical trial of AKCEA-APOCIII-LRx anticipated in early 2020 Data from Phase 2 clinical trial of AKCEA-APOCIII-LRx anticipated in early 2020

GlobeNewsWire - 1 year ago

Lynne Parshall appointed chair and Barbara Yanni joins as new member of the Akcea board Lynne Parshall appointed chair and Barbara Yanni joins as new member of the Akcea board

Benzinga - 1 year ago

Biotech investment is risk fraught. Most biotech stocks are at the mercy of binary events, which serve as make-or-break catalysts.

Other stocks mentioned: AMAG, AXSM, CRON, EIDX, HRTX, LGND, PRTK, PTE, VKTX, XON, ZIOP
GlobeNewsWire - 1 year ago

Alex Howarth joins Akcea from Lycera, bringing more than 25 years of experience in the biopharmaceutical sector Alex Howarth joins Akcea from Lycera, bringing more than 25 years of experience ...

About AKCA

Akcea Therapeutics, a biopharmaceutical company, focuses on developing and commercializing medicines to treat patients with serious and rare diseases in the United States and internationally. The company offers TEGSEDI, an antisense medicine designed to reduce the production of transthyretin protein. It develops WAYLIVRA, which has completed Phase III clinical study for the treatment of familial chylomicronemia syndrome, as well as is in Phase III clinical study for the treatment of familial partial lipodystrophy. The company also develops AKCE... [Read more...]

Industry
Biotechnology
IPO Date
Jul 14, 2017
CEO
Damien McDevitt
Employees
294
Stock Exchange
NASDAQ
Ticker Symbol
AKCA
Full Company Profile

Financial Performance

Financial Statements